 Role new cephamycins management obstetric gynecologic infections results vitro vivo studies cefmetazole second-generation cephamycin Cefmetazole spectrum activity clinical coverage many Enterobacteriaceae staphylococci streptococci Haemophilus species pathogenic Neisseria organisms Moraxella Branhamella catarrhalis anaerobic bacteria Cefmetazole times potent cefoxitin organisms spectra active staphylococci minimal inhibitory micrograms/mL Methicillin-resistant Staphylococcus aureus strains susceptible combination fosfomycin cephamycins cefmetazole resistant beta-lactamases aerobic anaerobic bacteria incidence adverse drug reactions low United Japan drug cost-containment potential